Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 8

recruiting
3 968
countries
28
conditions
2 103

160 trials match your criteria

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Breast cancer

Not yet recruiting

Study of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Colon cancer+3

Not yet recruiting

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Abemaciclib

Gastric cancer+1

Not yet recruiting

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Pancreatic carcinoma+2

Not yet recruiting

Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib

Breast cancer metastatic

Not yet recruiting

Personalizing treatment for patients with HR-positive, HER2-negative metastatic breast cancer using fulvestrant, elacestrant, capivasertib, capecitabine, or a drug combination.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Rectal cancer

Not yet recruiting

A Study of Watchful Waiting After Chemotherapy and Radiotherapy Compared to Surgery for Patients with Early Rectal Cancer Using Capecitabine

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Colorectal cancer

Not yet recruiting

Study of ipilimumab, nivolumab, temozolomide and capecitabine in patients with chemotherapy-resistant metastatic colorectal cancer with specific genetic markers

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Salivary gland cancer

Not yet recruiting

Study of Capecitabine for Patients with Recurrent or Metastatic Salivary Duct Carcinoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Colon cancer

Not yet recruiting

Study on Pembrolizumab and Drug Combination for Patients with Localized Colon Cancer with Specific Genetic Markers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Colon cancer stage III+1

Not yet recruiting

Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.